CoChat

Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01)

Open access

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Introduction: Aim of the present study was to evaluate the real-world impact of once-weekly (OW) subcutaneous semaglutide on different end-points indicative of metabolic control, cardiovascular risk factors, and beta-cell function in type 2 diabetes (T2D). Methods: This was a retrospective, observational study conducted in 5 diabetes clinics in Italy. Changes in HbA1c, fasting blood glucose (FBG), body weight, blood pressure, lipid profile, renal function, and beta-cell function (HOMA-B) during 12 months were evaluated. Results: Overall, 594 patients (97% GLP-1RA naïve) were identified (mean age 63.9 ± 9.5 years, 58.7% men, diabetes duration 11.4 ± 8.0 years). After 6 months of treatment with OW semaglutide, HbA1c levels were reduced by 0.90%, FBG by 26 mg/dl, and body weight by 3.43 kg. Systolic blood pressure, total and LDL-cholesterol significantly improved. Benefits were sustained at 12 months. Renal safety was documented. HOMA-B increased from 40.2% to 57.8% after 6 months (p<0.0001). Discussion: The study highlighted benefits of semaglutide on metabolic control, multiple CV risk factors, and renal safety in the real-world. Semaglutide seems to be an advisable option for preservation of β-cell function and early evidence suggests it might have a role in modifying insulin resistance (HOMA-IR), the pathogenetic basis of prediabetes and T2D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2022.1099451

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Changes in estimated mean levels of HbA1c after 6 and 12 months from semaglutide initiation.
Figure 1 Changes in estimated mean levels of HbA1c after 6 and 12 months from semaglutide initiation.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 2

  1. Di Folco, 2022, Effects of semagltide on cardiovascular risk factor and eating behaviours in type 2 diabetes, Acta Diabetol, 59, 10.1007/s00592-022-01936-6 · DOI · Paper page
  2. Di Loreto, 2022, Effectiveness in real world of once weekly semaglutide in people with type 2 diabetes: Glucagon-like peptide receptor agonist naive or switchers from other glucagon-like peptide receptor agonists: Results from a retrospective observational study in umbria, Diabetes Ther, 13, 10.1007/s13300-022-01218-y · DOI · Paper page

Cited by

See all 29

Metadata

Authors
Berra, C. C., Rossi, M. C., Mirani, M., Ceccarelli Ceccarelli, D., Romano, C., Sassi, L., Peretti, E., Favacchio, G., Pastore, I., Folini, L., Graziano, G., Lunati, M. E., Solerte, S. B., & Fiorina, P.
Affiliations
  • MultiMedica (IT)
  • Center for Outcomes Research and Clinical Epidemiology (IT)
  • IRCCS Humanitas Research Hospital (IT)
  • Ospedale di Circolo e Fondazione Macchi (IT)
  • ASST Fatebenefratelli Sacco (IT)
  • University of Pavia (IT)
  • University of Milan (IT)
Corresponding author
  • Berra, Cesare C.
  • Rossi, Maria Chiara
Venue
Frontiers in Endocrinology
Published
2023-01-18
Volume
13
Pages
1099451-1099451
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4317107805
Cited by
28
References
49
Citations by year
2026: 4 · 2025: 12 · 2024: 7 · 2023: 5
FWCI
5.74
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
semaglutide, type 2 diabetes, GLP-1 receptor agonists, glycemic control, HbA1c, fasting blood glucose, weight loss, blood pressure, lipid profile, renal safety, beta-cell function, HOMA-β, insulin resistance, cardiovascular risk factors, real-world effectiveness
MeSH terms
Semaglutide, Aged, Body Weight, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Retrospective Studies, Cohort Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01). https://app.cochat.ai/papers/10.3389/fendo.2022.1099451
The paper
Berra, C. C., Rossi, M. C., Mirani, M., Ceccarelli Ceccarelli, D., Romano, C., Sassi, L., Peretti, E., Favacchio, G., Pastore, I., Folini, L., Graziano, G., Lunati, M. E., Solerte, S. B., & Fiorina, P. (2023). Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01). Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2022.1099451

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.